Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.
KaloBios announces retirement of CFO
On the heels of KaloBios going public, Jeffrey Cooper is retiring as chief financial officer of the San Francisco-based antibody developer. Cooper's retirement is effective Dec. 31. He will stay at the company full-time until mid-November and as a part-time adviser until the end of the calendar year. Cooper joined KaloBios in July 2012. Previously, he served as senior vice president and chief financial officer of BioMarin Pharmaceutical ($BMRN). Release
|
Biotech
> NuMe Health has changed its name to MicroBiome Therapeutics and has hired Steve Orndorff as CEO. Previously, Orndorff was CEO of Ariel Pharmaceuticals. Release
> James Mazzo was appointed Neurotech Pharmaceuticals' executive chairman. Mazzo was formerly CEO of Abbott Medical Optics, is an operating partner at Versant Ventures and was recently named chairman and CEO of AcuFocus, a Versant portfolio company. Release
> Vincent Aurentz has joined HemoShear as the company's chief business officer. Aurentz previously was executive vice president of the Customer Solutions Business at Quintiles ($Q). Release
> Hyperion Therapeutics ($HPTX) has hired Larry J. Singer as vice president, Manufacturing. Previously, Singer held positions at Elan Pharmaceuticals ($ELN), Gilead Sciences ($GILD), Dey Laboratories, Syntex and Wyeth Laboratories. Release
> Lewis Barrett has joined Synthetic Biologics ($SYN) as its senior vice president, Commercial Strategy. Barrett is the former assistant vice president of Established Products at Pfizer ($PFE) and vice president global business manager of Infectious Diseases at Wyeth Pharmaceuticals. Release
> NeoStem has appointed Douglas Losordo as chief medical officer. Most recently, Losordo was vice president, New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International ($BAX). Release
> Gary Altman is taking on the positions of president, CEO and a member of the board of directors at Caldera Pharmaceuticals. Release
> Clearside Biomedical named Glenn Noronha its executive vice president of research and development. Release
> AIT Laboratories announced that R. Matthew Neff would be its new CEO and president, as well as retain his role as chairman of the board. Release
> Tengion promoted A. Brian Davis to be the company's senior vice president of finance in addition to his current position as chief financial officer. Release
Pharma
> Merz North America appointed John Donofrio as the company's chief financial officer and head of North American business development. Release
> Deborah DuFresne joined InnoPharma as vice president of strategic portfolio selection and management. DuFresne was formerly a senior director at Impax Laboratories. Release
> Alan Copa joined Novum Pharmaceutical Research Services as the company's vice president to lead its clinical expansion. Release
Drug Delivery
> Elite Pharmaceuticals brought on Nasrat Hakim as its president, CEO and member of the board of directors. Hakim previously worked for Actavis ($ACT), Watson ($WPI) and Alpharma in senior management. Release